Overall survival · treatment of relapsed epithelial ovarian cancer
EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Progression‐free survival · treatment of relapsed epithelial ovarian cancer
It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes progression‐free survival compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Grade 3 to 4 rash · treatment of relapsed epithelial ovarian cancer
It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes toxicity: grade 3 or 4 rash compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Toxicity: grade 3 or 4 nausea ± vomiting · treatment of relapsed epithelial ovarian cancer
It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes toxicity: grade 3 or 4 nausea ± vomiting compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Toxicity: grade 3 or 4 fatigue · treatment of relapsed epithelial ovarian cancer
It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes toxicity: grade 3 or 4 fatigue compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Toxicity: cardiac toxicity (any grade) · treatment of relapsed epithelial ovarian cancer
EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy showed no clear difference in toxicity: cardiac toxicity (any grade) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival · people with metastatic colorectal cancer ‐ KRAS exon 2 WT
The intervention leads to lower progression‐free survival (high certainty).
1 finding from 1 review
Intervention not reported
Overall survival · people with metastatic colorectal cancer ‐ KRAS exon 2 MT
The intervention showed no clear difference in overall survival (high certainty).
1 finding from 1 review
Intervention not reported
Tumour response rate · people with metastatic colorectal cancer ‐ KRAS exon 2 MT
The intervention showed no clear difference in tumour response rate (high certainty).
1 finding from 1 review
Intervention not reported
Overall grade 3 to 4 toxicity · people with metastatic colorectal cancer ‐ KRAS exon 2 MT
It is very uncertain whether the intervention changes overall grade 3 to 4 toxicity (very low certainty).
1 finding from 1 review
Intervention not reported
Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer ‐ KRAS exon 2 MT
The intervention may leads to higher grade 3 to 4 diarrhoea (low certainty).
1 finding from 1 review
Intervention not reported
Grade 3 to 4 rash · people with metastatic colorectal cancer ‐ KRAS exon 2 MT
The intervention probably leads to higher grade 3 to 4 rash (moderate certainty).
1 finding from 1 review
Intervention not reported
Grade 3 to 4 neutropenia · people with metastatic colorectal cancer ‐ KRAS exon 2 MT
The intervention leads to lower grade 3 to 4 neutropenia (high certainty).
1 finding from 1 review
Intervention not reported
Quality of life · people with metastatic colorectal cancer ‐ KRAS exon 2 MT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Progression‐free survival · people with metastatic colorectal cancer ‐ extended RAS WT
The intervention probably leads to lower progression‐free survival (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall survival · people with metastatic colorectal cancer ‐ extended RAS WT
The intervention leads to lower overall survival (high certainty).
1 finding from 1 review
Intervention not reported
Tumour response rate · people with metastatic colorectal cancer ‐ extended RAS WT
The intervention probably leads to higher tumour response rate (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall survival · people with metastatic colorectal cancer ‐ KRAS exon 2 WT
The intervention leads to lower overall survival (high certainty).
1 finding from 1 review
Intervention not reported
Overall grade 3 to 4 toxicity · people with metastatic colorectal cancer ‐ extended RAS WT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer ‐ extended RAS WT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found